Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
about
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesDPP-4 inhibition and islet functionLinagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityOptimal therapy of type 2 diabetes: a controversial challengeDipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female miceInfluence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Molecular insights from bariatric surgery.The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsA Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating AgentsEfficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiationPotential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesLong-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studySafety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsComparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetesEffects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers.Linagliptin as add-on therapy to insulin for patients with type 2 diabetesOL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.A review of the efficacy and safety of oral antidiabetic drugsLinagliptin: farmacology, efficacy and safety in type 2 diabetes treatmentClinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.
P2860
Q26749524-EE48A9B6-69AC-4A74-8399-55827BA2D4C7Q26785454-8888F0DC-7591-4A1C-B9B4-C47D9F076ACDQ27028127-B1B6F46B-BF06-4917-ADA3-0686215E89E3Q28728101-371B9921-68CC-41D1-9E2F-9CD7B6808CCFQ33577712-AFD3766C-A457-4A0D-B057-2EB559466C7BQ33644666-979161EB-FB77-4B71-BA66-AA0696D6CF5BQ33990778-BB0E37BC-D19A-47A4-97E0-2C2D2D571225Q34219918-CE4C3E6B-8B9C-4909-9163-27090661F2A2Q34978864-7E974C93-AD14-45F5-9390-FB882EC24039Q35120585-EE245643-8480-4B00-9462-BED7A82133F2Q35330816-44846656-5DFA-4585-B044-E03C0A20003DQ35736564-8BCEFD04-5732-46CA-AE65-B0A99C39528BQ35743729-E85CD3B2-7D1F-4882-BC22-36FFD8E00BFEQ35752928-975C0314-122C-41EB-9531-DC23D5A79F23Q35777074-CBD7249B-E6CF-47EC-8816-3A828ACC0757Q35800419-AE4F7083-DC50-4458-A8D6-DFC2ABD3AEFAQ35916947-2B7FDB6A-382B-48D1-A608-3FBDCC5FBB6BQ36196649-CD379291-BE8A-4F76-9EC0-8AD0D3C5A721Q36428096-7C87CAD2-04E7-4840-9D6A-7BEAC718782BQ36520758-AB0CEE5A-EA2A-4CE9-B03D-8466227DBFF6Q36560252-F3615E58-77C6-4FA1-B38A-3ECA262E477BQ36883337-B8992F05-3C00-47AC-BF56-3BB8B06B0CAEQ36946065-E4EBBCA6-06E6-4E21-9F24-7511363290D7Q37227407-449720D7-64E1-4ABC-974D-F280E793C996Q37248403-71FB4FD3-101B-46D4-AE48-A5135F568E98Q37281205-A83EAC6B-7E2B-4A38-B622-E970FB15DF9BQ37325663-63D39D49-EAE6-4698-B2FE-14CBD86FBB5FQ37779101-92FDB55D-333A-40F9-956C-3EDF99200241Q37858364-9BD6CEA0-FA04-42E7-B384-F381ED2CE9A9Q37866299-3EB25322-6419-4772-BDEE-AA3762702D05Q37948831-F446C147-B6D5-4CC9-A401-6C109E693B58Q37965613-95AB3AC7-E086-4571-A129-F0376F8A0E85Q37992956-F08B9D36-B214-48FB-9B4E-91F0BCD2EBBFQ38012068-45732131-2FCF-4684-AA57-7C9AF2CC2B9FQ38062881-228EB4D4-1D90-4F98-9C3B-72FCE4E34389Q38067491-BAE92E67-F394-4384-B791-FDB926F9CF93Q38108636-E9F0A08B-1C1A-4C8A-B29D-DF7273D5EE51Q38113093-6D2C0386-847E-4439-BAFE-192409FEB31DQ38152405-01ADC006-513B-4B96-84A2-0A8231D5197FQ38497122-2DDD6C50-66D2-4B9D-AE15-48426277CAB6
P2860
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Linagliptin, a xanthine-based ...... treatment of type 2 diabetes.
@en
Linagliptin, a xanthine-based ...... treatment of type 2 diabetes.
@nl
type
label
Linagliptin, a xanthine-based ...... treatment of type 2 diabetes.
@en
Linagliptin, a xanthine-based ...... treatment of type 2 diabetes.
@nl
prefLabel
Linagliptin, a xanthine-based ...... treatment of type 2 diabetes.
@en
Linagliptin, a xanthine-based ...... treatment of type 2 diabetes.
@nl
P2860
P1476
Linagliptin, a xanthine-based ...... treatment of type 2 diabetes.
@en
P2860
P304
P356
10.1517/13543780903463862
P407
P577
2010-01-01T00:00:00Z